GlaxoSmithKline PLC ADR
$ 52.17
1.38%
06 Aug - close price
- Market Cap 103,064,379,000 USD
- Current Price $ 52.17
- High / Low $ 52.57 / 51.88
- Stock P/E 16.18
- Book Value 11.83
- EPS 3.18
- Next Earning Report -
- Dividend Per Share $0.68
- Dividend Yield 3.53 %
- Next Dividend Date 2026-10-08
- ROA 0.10 %
- ROE 0.33 %
- 52 Week High 60.65
- 52 Week Low 36.31
About
GlaxoSmithKline plc is dedicated to the creation, discovery, development, manufacture and marketing of pharmaceuticals, vaccines, over-the-counter drugs and health-related consumer products in the UK, US and internationally. The company is headquartered in Brentford, the United Kingdom.
Analyst Target Price
$58.08
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-07-28 | 2026-04-29 | 2026-02-04 | 2025-10-29 | 2025-07-30 | 2025-04-30 | 2025-02-05 | 2024-10-30 | 2024-07-31 | 2024-05-01 | 2024-01-31 | 2023-11-01 |
| Reported EPS | 1.36 | 1.26 | 0.7 | 1.46 | 1.24 | 1.2 | 0.58 | 1.29 | 1.11 | 1.08 | 0.73 | 1.22 |
| Estimated EPS | 1.27 | 1.16 | 0.62 | 1.26 | 1.11 | 1.04 | 0.49 | 1.16 | 0.98 | 0.94 | 0.77 | 1.14 |
| Surprise | 0.09 | 0.1 | 0.08 | 0.2 | 0.13 | 0.16 | 0.09 | 0.13 | 0.13 | 0.14 | -0.04 | 0.08 |
| Surprise Percentage | 7.0866% | 8.6207% | 12.9032% | 15.873% | 11.7117% | 15.3846% | 18.3673% | 11.2069% | 13.2653% | 14.8936% | -5.1948% | 7.0175% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Previous Dividend Records
| Oct 2026 | Jul 2026 | Jan 1970 | Jan 2026 | Jan 1970 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-10-08 | 2026-07-09 | None | 2026-01-08 | None | 2025-07-10 | 2025-04-10 | 2025-01-09 | 2024-10-10 | 2024-07-11 |
| Amount | $0.45152 | $0.461074 | $0.485604 | $0.417088 | $0.428118 | $0.429088 | $0.400652 | $0.389052 | $0.385671 | $0.376185 |
Next Dividend Records
| Dividend per share (year): | $0.68 |
| Dividend Yield | 3.53% |
| Next Dividend Date | 2026-10-08 |
| Ex-Dividend Date | 2026-08-14 |
Recent News: GSK
2026-08-05 03:12:54
GSK announced a £400 million investment to establish a new global R&D center in Cambridge, UK. This strategic move aims to accelerate GSK's R&D pipeline and integrate the company further into Cambridge's world-class biomedical research ecosystem. The new facility will house over 1,000 scientists and focus on areas like Oncology, Respiratory, Hepatology, Vaccines, and HIV, while also upgrading existing R&D labs in Ware, Hertfordshire.
2026-08-03 15:10:12
GSK plc has reported its total voting rights as 4,045,411,246 as of July 31, 2026, in accordance with the Financial Conduct Authority's disclosure requirements. The company's issued share capital included 4,316,292,310 Ordinary Shares, with 270,881,064 of these held in Treasury, which do not carry voting rights. This figure is crucial for shareholders to determine their notification obligations regarding changes in their interests under the Disclosure Guidance and Transparency Rules.
2026-08-03 11:28:00
GlaxoSmithKline Pharmaceuticals (GSK India) reported a 15.7% increase in first-quarter profit, driven by stable demand for its vaccine and drug portfolio. The company's revenue from operations rose by 16.6%, and it plans to launch new treatments, including Blenrep for multiple myeloma and the Arexvy vaccine. Analysts anticipate improved long-term growth visibility for GSK India due to its stronger global specialty pipeline and innovation-led portfolio transition.
2026-08-03 08:44:33
Bernstein analyst Justin Smith has issued a "Buy" rating for GSK stock, revising the target price upwards from GBX 2825 to GBX 3010. This recommendation suggests a positive outlook for the pharmaceutical group, which is the world's second-largest by net sales. The report highlights GSK's diverse product portfolio, including pharmaceutical products, OTC medicine, and vaccines.
2026-08-01 04:41:30
This article focuses on the "Price to earnings forward" metric for GSK plc, listed on the London Stock Exchange under the ticker GSK. It appears to be a financial data snippet from a larger platform like TradingView, providing specific financial information without extensive commentary or news.
2026-07-30 23:39:50
GSK plc announced that Regis Simard, President of Global Supply Chain, sold 38,000 Ordinary Shares at a price of £20.3800 per share on July 29, 2026. This transaction was an initial notification and took place on the London Stock Exchange.
